[go: up one dir, main page]

HRP20030097A2 - Use of strains of the parapox ovis virus against organ fibrosis - Google Patents

Use of strains of the parapox ovis virus against organ fibrosis

Info

Publication number
HRP20030097A2
HRP20030097A2 HR20030097A HRP20030097A HRP20030097A2 HR P20030097 A2 HRP20030097 A2 HR P20030097A2 HR 20030097 A HR20030097 A HR 20030097A HR P20030097 A HRP20030097 A HR P20030097A HR P20030097 A2 HRP20030097 A2 HR P20030097A2
Authority
HR
Croatia
Prior art keywords
strains
organ fibrosis
virus against
against organ
parapox ovis
Prior art date
Application number
HR20030097A
Other languages
English (en)
Inventor
Hirth-Dietrich Claudia
Schlapp Tobias
Siegling Angela
Knorr Andreas
Weber Olaf
Theiss Gudrun
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10122233A external-priority patent/DE10122233A1/de
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Publication of HRP20030097A2 publication Critical patent/HRP20030097A2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR20030097A 2000-07-11 2001-07-11 Use of strains of the parapox ovis virus against organ fibrosis HRP20030097A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10033581 2000-07-11
DE10122233A DE10122233A1 (de) 2000-07-11 2001-05-08 Verwendung von Stämmen des Parapoxvirus ovis gegen Organfibrosen
PCT/EP2001/007978 WO2002004019A2 (de) 2000-07-11 2001-07-11 Verwendung von stämmen des parapoxvirus ovis gegen organfibrosen

Publications (1)

Publication Number Publication Date
HRP20030097A2 true HRP20030097A2 (en) 2005-02-28

Family

ID=26006334

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030097A HRP20030097A2 (en) 2000-07-11 2001-07-11 Use of strains of the parapox ovis virus against organ fibrosis

Country Status (30)

Country Link
US (1) US6632647B2 (es)
EP (1) EP1303302B1 (es)
JP (1) JP5106736B2 (es)
CN (1) CN1452496B (es)
AR (1) AR028800A1 (es)
AU (2) AU8582701A (es)
BG (1) BG107447A (es)
CA (1) CA2415399C (es)
CZ (1) CZ200372A3 (es)
DK (1) DK200300014A (es)
EE (1) EE200300019A (es)
FI (1) FI20030038A7 (es)
GB (1) GB2383752B (es)
HK (1) HK1054330B (es)
HR (1) HRP20030097A2 (es)
HU (1) HU227668B1 (es)
IL (1) IL153826A0 (es)
LT (1) LT5064B (es)
LU (1) LU90996B1 (es)
LV (1) LV12991B (es)
MA (1) MA25765A1 (es)
MX (1) MXPA03000278A (es)
NO (1) NO20030081D0 (es)
NZ (1) NZ523535A (es)
PL (1) PL360839A1 (es)
RU (1) RU2003104522A (es)
SE (1) SE0300033L (es)
SI (1) SI21171A (es)
SK (1) SK382003A3 (es)
WO (1) WO2002004019A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19922407A1 (de) * 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
US6752995B2 (en) 2002-04-15 2004-06-22 Board Of Regents, The University Of Texas System Nucleic acid and polypeptide sequences useful as adjuvants
EP1499355A4 (en) 2001-12-07 2005-10-05 Bayer Pharmaceuticals Corp USE OF PARAPOX B2L PROTEIN FOR THE TREATMENT OF CANCER AND THE MODIFICATION OF IMMUNE RESPONSES
EP1574211A1 (en) 2004-03-09 2005-09-14 Inserm Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
WO2012045473A1 (en) * 2010-10-07 2012-04-12 Technische Universität München Viruses for the treatment of fibrosis
EA201891848A1 (ru) 2016-02-16 2019-02-28 Осака Юниверсити Фармацевтическая композиция для применения в лечении фиброза
TW201919675A (zh) * 2017-09-07 2019-06-01 德商艾庫瑞斯公司 使用羊副痘疹病毒(Parapoxvirus ovis；PPVO)及至少一種額外抗病毒藥之經B型肝炎病毒(HBV)感染之個體之組合療法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714665A1 (de) * 1977-04-01 1978-10-05 Mayr Anton Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
US4360510A (en) * 1979-11-30 1982-11-23 Proctor Julian W Method for screening anti-tumor agents of the reticulo-endothelial stimulant class
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
DE3504940C2 (de) 1984-02-17 1997-11-06 Bayer Ag Multipotente Paramunitätsmediatoren, Verfahren zu ihrer Herstellung und diese Mediatoren enthaltende Arzneimittel
DE3816139A1 (de) * 1987-10-17 1989-04-27 Bayer Ag Verfahren zur herstellung von paramunitaetsinducern
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ATE203678T1 (de) * 1996-04-15 2001-08-15 Anton Prof Dr Med Vet Dr Mayr Verwendung von multipotenten paramunitätsinducern aus attenuierten, nicht-immunogenen pockenviren oder parapockenviren zur herstellung von arzneimitteln
DE19922407A1 (de) * 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
IL139593A (en) * 2000-11-09 2010-12-30 Biogem Optical Ltd Method for the detection of viable microorganisms

Also Published As

Publication number Publication date
GB2383752A (en) 2003-07-09
LT5064B (lt) 2003-11-25
AU8582701A (en) 2002-01-21
CN1452496B (zh) 2012-10-10
HUP0303830A2 (hu) 2004-04-28
HU227668B1 (en) 2011-11-28
NZ523535A (en) 2004-12-24
EP1303302A2 (de) 2003-04-23
MA25765A1 (fr) 2003-04-01
HK1054330A1 (en) 2003-11-28
DK200300014A (da) 2003-03-07
HUP0303830A3 (en) 2004-10-28
SI21171A (sl) 2003-10-31
HK1054330B (zh) 2005-07-15
CZ200372A3 (cs) 2003-05-14
IL153826A0 (en) 2003-07-31
EE200300019A (et) 2004-10-15
CA2415399A1 (en) 2003-01-08
US20020076418A1 (en) 2002-06-20
US6632647B2 (en) 2003-10-14
NO20030081L (no) 2003-01-08
EP1303302B1 (de) 2009-10-14
AU2001285827B2 (en) 2006-11-30
LT2003008A (en) 2003-07-25
JP2004502741A (ja) 2004-01-29
WO2002004019A3 (de) 2002-08-01
SK382003A3 (en) 2003-07-01
LU90996B1 (en) 2003-01-08
LV12991B (en) 2003-08-20
RU2003104522A (ru) 2004-06-27
CN1452496A (zh) 2003-10-29
JP5106736B2 (ja) 2012-12-26
SE0300033D0 (sv) 2003-01-10
NO20030081D0 (no) 2003-01-08
SE0300033L (sv) 2003-03-10
GB2383752B (en) 2004-11-24
CA2415399C (en) 2011-11-08
FI20030038A7 (fi) 2003-03-10
PL360839A1 (pl) 2004-09-20
BG107447A (bg) 2003-09-30
WO2002004019A2 (de) 2002-01-17
MXPA03000278A (es) 2004-04-05
AR028800A1 (es) 2003-05-21
GB0302629D0 (en) 2003-03-12

Similar Documents

Publication Publication Date Title
AU2001244675A1 (en) Aids virus vaccine with the use of sendai virus vector
SI1410805T1 (sl) Cepivo proti HPV
AU2002219135A1 (en) Substituted 2-anilino-benzimidazoles and the use thereof as NHE-inhibitors
IL153879A0 (en) Modified virus
HRP20030096A2 (en) Use of strains of the parapox ovis virus for producing pharmacuticals and anticancer pharmaceuticals
AU2001270631A1 (en) Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals
AU2001270631A2 (en) Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals
GB2383752B (en) Use of strains of the parapox ovis virus against organ fibrosis
AU2001285827A2 (en) Use of strains of the parapox ovis virus against organ fibrosis
AU2001285827A1 (en) Use of strains of the parapox ovis virus against organ fibrosis
AU2756301A (en) Compositions comprising genome segments and methods of using the same
GB0001475D0 (en) Virus strains
AU2002220416A1 (en) Oncolytic virus
AU2001233588A1 (en) New toralactone and its derivation and the use of decreasing blood-fat and losing weight
AU8609201A (en) Reduction of the electrocardiographic ot interval
HUP0302964A3 (en) Delta 1-pyrrolines, intermediates, preparation thereof and their use as pesticides
GB0002854D0 (en) Virus strains
EP1315507A4 (en) HPV-SPECIFIC SHORT OLIGOMERS
GB0100430D0 (en) Virus strains
GB0100288D0 (en) Virus strains
HK1058475A (en) Oncolytic virus therapy
GB0011221D0 (en) Viral preparations and their production and use
HRPK20010137B1 (en) Propeller using the force of the wind
GB0103731D0 (en) Materials and methods relating to increasing viral tissue
AU2001224042A1 (en) Grip end bottom additional-weighting weight, and grip end bottom additional-weighting structure

Legal Events

Date Code Title Description
A1OB Publication of a patent application
OBST Application withdrawn